Form 4: Evoke Pharma Director Benjamin C. Smeal Acquires Stock Options
SEC Form 4 Filing
Director Benjamin C. Smeal of Evoke Pharma acquired stock options exercisable for 1,125 shares of common stock on May 21, 2025.
Summary
- On May 21, 2025, Benjamin C. Smeal, a director of Evoke Pharma Inc., acquired stock options.
- These options grant the right to buy 1,125 shares of Evoke Pharma's common stock at an exercise price of $3.453 per share.
- The options vest one year from the grant date, contingent upon Smeal's continued service to the company.
- Following this transaction, Smeal directly owns 6,958 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing regarding stock option grants. It indicates confidence from the director but doesn't provide substantial information about the company's overall performance.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting conditions of the stock options.
Industry Context
This is a standard disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Comparison to Industry Standards
- Stock option grants are a common component of compensation packages for directors and executives in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to align the interests of their management with those of shareholders.
- The vesting schedule of one year is fairly standard, aligning with typical industry practices for incentivizing long-term commitment.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of the stock option transaction. |
| 05/20/2035 | Expiration date of the stock options. |
Keywords
Evoke Pharma, Stock Options, Form 4, Director, Beneficial Ownership, EVOK, Smeal, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.